Biogen will return the rights to Aduhelm to Neurimmune, the private firm that invented it, the company said. Photo by MART PRODUCTION/Pexels Biogen, maker of the Alzheimer's medicine Aduhelm, ...

Biogen will stop developing its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster before stumbling soon after its launch a couple years ago. The drugmaker said Wednesday that ...

Drugmaker Biogen is pulling the plug on its controversial Alzheimer's drug Aduhelm, following disappointing sales. It had been expected to be a blockbuster product. A drugmaker is pulling the plug on ...

More than two years after Aduhelm's controversial and ill-fated FDA accelerated approval, Biogen is discontinuing the Alzheimer's disease therapy after walking a rocky path. Wednesday, Biogen said ...

The Congressional report on the FDA’s approval of Aduhelm makes some good points. As regulatory science advances, so too must the FDA’s administrative procedures. But this report mustn’t be seen as an ...

Please provide your email address to receive an email when new articles are posted on . Biogen announced a reprioritization of resources regarding its pipeline of therapeutics to address Alzheimer’s ...

There has been considerable controversy surrounding Aduhelm since the Food and Drug Administration (FDA) granted the drug accelerated approval in 2021. The accelerated approval of Aduhelm has been ...